IRIS
LODOLA, Alessio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.138
NA - Nord America 4.793
AS - Asia 3.096
SA - Sud America 462
AF - Africa 93
Continente sconosciuto - Info sul continente non disponibili 6
Totale 13.588
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.693
IT - Italia 1.311
CN - Cina 1.215
SG - Singapore 1.039
IE - Irlanda 825
FI - Finlandia 802
SE - Svezia 639
DE - Germania 586
BR - Brasile 410
HK - Hong Kong 384
UA - Ucraina 230
NL - Olanda 186
TR - Turchia 183
IN - India 112
FR - Francia 106
GB - Regno Unito 103
CA - Canada 87
AT - Austria 83
RU - Federazione Russa 79
CI - Costa d'Avorio 69
BE - Belgio 60
VN - Vietnam 41
CZ - Repubblica Ceca 35
ID - Indonesia 23
ES - Italia 19
AR - Argentina 18
JP - Giappone 15
PK - Pakistan 15
RO - Romania 12
BD - Bangladesh 11
LT - Lituania 11
PL - Polonia 11
VE - Venezuela 11
JO - Giordania 10
ZA - Sudafrica 9
EC - Ecuador 7
IQ - Iraq 7
MX - Messico 7
HR - Croazia 5
HU - Ungheria 5
IL - Israele 5
MA - Marocco 5
AL - Albania 4
CH - Svizzera 4
CO - Colombia 4
EU - Europa 4
NP - Nepal 4
PY - Paraguay 4
AZ - Azerbaigian 3
BO - Bolivia 3
CR - Costa Rica 3
DK - Danimarca 3
IR - Iran 3
JM - Giamaica 3
KG - Kirghizistan 3
NO - Norvegia 3
SA - Arabia Saudita 3
TH - Thailandia 3
TW - Taiwan 3
UZ - Uzbekistan 3
BG - Bulgaria 2
BY - Bielorussia 2
CL - Cile 2
CY - Cipro 2
DZ - Algeria 2
EG - Egitto 2
KE - Kenya 2
MD - Moldavia 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
UY - Uruguay 2
A1 - Anonimo 1
AE - Emirati Arabi Uniti 1
EE - Estonia 1
KR - Corea 1
LB - Libano 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
MC - Monaco 1
MY - Malesia 1
NG - Nigeria 1
OM - Oman 1
PE - Perù 1
PS - Palestinian Territory 1
PT - Portogallo 1
RS - Serbia 1
SC - Seychelles 1
SN - Senegal 1
TJ - Tagikistan 1
TM - Turkmenistan 1
TN - Tunisia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 13.588
Salva come PNG Salva come JPEG
Città #
Dublin 818
Chandler 742
Singapore 587
Parma 491
Santa Clara 442
Ann Arbor 398
Hong Kong 377
Ashburn 297
Jacksonville 293
Beijing 261
Dearborn 246
Boardman 221
Munich 210
Nanjing 163
Izmir 160
Shanghai 152
Helsinki 143
Princeton 136
New York 114
Wilmington 112
Bremen 79
Milan 79
San Mateo 77
Hefei 74
Abidjan 69
Shenyang 67
Vienna 64
Los Angeles 62
Toronto 55
Brussels 53
Kunming 49
Moscow 48
Jinan 46
Bologna 44
Hebei 44
Nanchang 42
Council Bluffs 41
Düsseldorf 40
Seattle 38
The Dalles 38
Des Moines 37
Modena 37
São Paulo 35
Dong Ket 34
Turku 33
Brescia 32
Jiaxing 32
Guangzhou 31
Woodbridge 30
Changsha 29
London 29
Dallas 28
Bangalore 27
Fremont 27
Columbus 26
Frankfurt am Main 24
Jakarta 23
Nuremberg 22
Brno 20
Pune 20
Tianjin 20
Lubbock 19
Norwalk 18
Ottawa 18
Hangzhou 17
Zhengzhou 17
Ankara 16
Grafing 14
Reggio Emilia 14
Rio de Janeiro 14
Rome 14
Belo Horizonte 13
Dalmine 13
Prata Di Pordenone 12
Tokyo 12
Houston 11
Münster 11
Palermo 11
San Francisco 11
Verona 11
Amman 9
Auburn Hills 9
Bengaluru 9
Borås 9
Brasília 9
Curitiba 9
Fairfield 9
Marseille 9
Chicago 8
Montreal 8
Naples 8
Salvador 8
Taizhou 8
Weihai 8
Falls Church 7
Fuzhou 7
Genoa 7
Hyderabad 7
Neviano degli Arduini 7
Ningbo 7
Totale 8.496
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 233
A Pharmacological Investigation of Eph-Ephrin Antagonism in Prostate Cancer: UniPR1331 Efficacy Evidence 203
Inhibition of Eph/ephrin interaction with the small molecule UniPR500 improves glucose tolerance in healthy and insulin-resistant mice 182
Targeting the Eph/ephrin system as anti-inflammatory strategy in IBD 180
Benzisothiazolinone Derivatives as Potent Allosteric Monoacylglycerol Lipase Inhibitors That Functionally Mimic Sulfenylation of Regulatory Cysteines 175
Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. 157
UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. 155
Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3α-carbamoyloxy derivative with antiangiogenetic properties 152
Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction 147
inibitori eph-ephrin biodisponibili oralmente 141
Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach 140
Drug-gut microbiota metabolic interactions: the case of UniPR1331, selective antagonist of the Eph-ephrin system, in mice 138
Dibasic biphenyl H(3) receptor antagonists: Steric tolerance for a lipophilic side chain. 136
A catalytic mechanism for cysteine N-terminal nucleophile hydrolases, as revealed by free energy simulations 136
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 134
Application of 3D-QSAR in the Rational Design of Receptor Ligands and Enzyme Inhibitors 130
Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation 130
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 129
Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction 125
Amino acid derivatives as palmitoylethanolamide prodrugs: Synthesis, in vitro metabolism and in vivo plasma profile in rats 124
Development of an orally bioavailable small molecule targeting Eph-ephrin system: in vitro and in vivo anticancer activity. 122
N-Acylethanolamine Acid Amidase (NAAA): Structure, Function, and Inhibition 121
Metabolic Soft Spot and Pharmacokinetics: Functionalization of C-3 Position of an Eph–Ephrin Antagonist Featuring a Bile Acid Core as an Effective Strategy to Obtain Oral Bioavailability in Mice 121
NEW EPH ANTAGONISTS DISCRIMINATING BETWEEN EPH-AS AND EPH-BS CLASSES 118
5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity 118
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line 118
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 114
Design and structure-activity relationship of amino acid derivatives of lithocholic acid as novel EphA2 antagonists 113
Structure–Activity Relationships and Mechanism of Action of Eph–ephrin Antagonists: Interaction of Cholanic Acid with the EphA2 Receptor 112
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 111
Discovery of a new 1-(phenylsulfonyl)-1H-indole derivative targeting the EphA2 receptor with antiproliferative activity on U251 glioblastoma cell line 110
Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability 110
Free-Energy Simulations Support a Lipophilic Binding Route for Melatonin Receptors 109
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. 109
Application of a SCC-DFTB QM/MM approach to the investigation of the catalytic mechanism of fatty acid amide hydrolase. 107
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 105
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 105
N-Acylethanolamine Acid Amidase (NAAA): Mechanism of Palmitoylethanolamide Hydrolysis Revealed by Mechanistic Simulations 104
Discovery and development of small molecules targeting Eph-ephrin system in glioblastoma: an academic history 103
Development of 3-oxo-cholenic derivatives as Eph antagonists able to block in vitro angiogenesis 103
Multiple approaches for the discovery and development of small molecules targeting Eph-ephrin protein-protein interaction 103
Eph/ephrin targeting with a small molecule improves glucose tolerance in healthy and insulin-resistant mice 102
Protein-Protein Interaction Inhibitors Targeting the Eph-Ephrin System with a Focus on Amino Acid Conjugates of Bile Acids 102
PHARMACOLOGICAL CHARACTERIZATION OF NEW COMPOUNDS AIMED AT INHIBITING EPH-EPHRIN INTERACTION IN GLIOBLASTOMA 101
The ellagitannin colonic metabolite urolithin D selectively inhibits EphA2 phosphorylation in prostate cancer cells 101
Discovery and development of Eph-ephrin antagonists endowed with antiangiogenic properties 101
UniPR1331: small Eph/ephrin antagonist beneficial in intestinal inflammation by interfering with type-B signaling 101
A critical cysteine residue in monoacylglycerol lipase is targeted by a new class of isothiazolinone-based enzyme inhibitors. 99
Cyclohexylcarbamic Acid 3'- or 4'-Substituted Biphenyl-3-yl Esters of as Fatty Acid Amide Hydrolase Inhibitors: Synthesis, Quantitative Structure-Activity Relationships and Molecular Modelling Studies 98
Design and structure-activity relationships of amino acid derivatives of lithocholic acid as novel EphA2 receptor antagonists. 98
Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists 98
Atropisomerism and Conformational Equilibria: Impact on PI3Kδ Inhibition of 2-((6-Amino-9H-purin-9-yl)methyl)-5-methyl-3-(o-tolyl)quinazolin-4(3H)-one (IC87114) and Its Conformationally Restricted Analogs 98
Eph-ephrin antagonism in tumor angiogenesis and growth: UniPR1331 preclinical evidence. 97
Discovery and development of low molecular weight Eph-ephrin protein-protein inhbi-tors endowed with antiangiogenic activity 95
Evaluation of the anti-tumor activity of small molecules targeting eph/ephrins in apcmin j mice 95
270 Discovery, development and optimization of low molecular weight EPH–ephrin protein–protein inhibitors 94
QM/MM modelling of oleamide hydrolysis in fatty acid amide hydrolase (FAAH) reveals a new mechanism of nucleophile activation 94
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion 93
N-(2-Oxo-3-oxetanyl)carbamic Acid Esters as N-Acylethanolamine Acid Amidase Inhibitors: Synthesis, Structure–Activity and Structure–Property Relationships. 93
MT2 selective melatonin receptor antagonists: design and structure-activity relationships 92
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 92
UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice 92
Mechanism of inhibition of SARS-CoV-2 MprobyN3peptidyl Michael acceptor explained by QM/MM simulations and design of new derivatives with tunable chemical reactivity 91
Applications and Advances of QM/MM methods in Computational Enzymology 90
Aromatic interactions and rotational strengths within protein environment: An electronic structural study on beta-lactamases from class A 90
Metadynamics for perspective drug design: Computationally driven synthesis of new protein-protein interaction inhibitors targeting the EphA2 receptor 90
Irreversible EGFR inhibitor compounds with antiproliferative activity 89
Combining pharmacology, target hopping and computational medicinal chemistry to discover novel scaffold targeting EPH-ephrin interaction. 89
Synthesis, Pharmacological Evaluation and Structure-Activity Relationships of Benzopyran Derivatives with Potent SERM Activity 88
Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system 88
Pushing the Boundaries of Vinylogous Reactivity: Catalytic Enantioselective Mukaiyama Aldol Reactions of Highly Unsaturated 2-Silyloxyindoles 88
APPLICATION OF COMPUTATIONAL METHODSTO THE DESIGN OF FATTY ACID AMIDE HYDROLASE(FAAH) INHIBITORS BASED ON A CARBAMICTEMPLATE STRUCTURE 87
Identification of bivalent ligands with melatonin receptor agonist and fatty acid amide hydrolase (FAAH) inhibitory activity that exhibit ocular hypotensive effect in the rabbit 87
Exploiting Free-Energy Minima to Design Novel EphA2 Protein-Protein Antagonists: From Simulation to Experiment and Return 87
Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis 86
L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib 86
Catalytic, Asymmetric Hypervinylogous Mukaiyama Aldol Reactions of Extended Furan-Based Silyl Enolates 84
Target Hopping as a Useful Tool for the Identification of Novel EphA2 Protein–Protein Antagonists 84
N-tert-butyloxycarbonyl-Phe-Leu-Phe-Leu-Phe (BOC2) inhibits the angiogenic activity of heparin-binding growth factors. 84
Predicting the reactivity of nitrile-carrying compounds with cysteine: a combined computational and experimental study. 84
Tetrahydroquinoline Ring as a Versatile Bioisostere of Tetralin for Melatonin Receptor Ligands 84
Design and synthesis of N-(3,3-diphenylpropenyl)alkanamides as a novel class of high-affinity MT2-selective melatonin receptor ligands. 83
Synthesis, Enantiomeric Resolution, and Structure-Activity Relationship Study of a Series of 10,11-Dihydro-5H-Dibenzo[a,d]cycloheptene MT(2) Receptor Antagonists. 83
Structure activity relationship of new EphA2 ligands 83
Analysis of adam12-mediated ephrin-a1 cleavage and its biological functions 83
Mechanistic Insights into the Reaction of Chlorination of Tryptophan Catalyzed by Tryptophan 7-Halogenase 82
Mechanistic Modeling of Lys745 Sulfonylation in EGFR C797S Reveals Chemical Determinants for Inhibitor Activity and Discriminates Reversible from Irreversible Agents 81
Lithocholic acid competitively inhibits EphA2-ephrinA1 binding: pharmacological and structural considerations. 80
Role of sphingolipid metabolism in osimertinib-resistance in EGFR-mutated NSCLC models 79
Lithocholic acid competitively inhibitis EphA2-ephrinA1 binding: pharmacological and structural considerations. 79
Metadynamics Simulations Distinguish Short- and Long-Residence-Time Inhibitors of Cyclin-Dependent Kinase 8. 79
Different roles for the acyl chain and the amine leaving group in the substrate selectivity of N-Acylethanolamine acid amidase 79
Lithocholic Acid Is an Eph-ephrin Ligand Interfering with Eph-kinase Activation. 78
Therapeutic perspectives of Eph–ephrin system modulation 77
Free-energy studies reveal a possible mechanism for oxidation-dependent inhibition of MGL 77
On the Use of 2,5-Dimethyl-Pyrrol-1-yl-Benzoic Acid Derivatives as EPH-Ephrin Antagonists. 77
Design and SAR Analysis of Covalent Inhibitors Driven by Hybrid QM/MM Simulations 76
Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors 76
Mechanistic Modeling of Monoglyceride Lipase Covalent Modification Elucidates the Role of Leaving Group Expulsion and Discriminates Inhibitors with High and Low Potency 75
Structure-property relationships of a class of carbamate-based fatty acid amide hydrolase (FAAH) inhibitors: chemical and biological stability 75
Totale 10.577
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.878
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.878
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202082 0 0 0 0 0 0 0 0 0 0 0 82
2020/20211.022 22 79 88 77 125 59 124 43 194 41 88 82
2021/2022850 30 24 24 86 58 28 109 100 58 67 35 231
2022/20233.112 314 309 172 240 288 358 41 196 983 45 127 39
2023/20241.256 82 72 42 43 89 270 118 111 46 64 142 177
2024/20254.383 137 217 271 250 455 481 273 263 563 399 382 692
Totale 13.924